Poolbeg Pharma PLC (POLB) - Total Assets
Based on the latest financial reports, Poolbeg Pharma PLC (POLB) holds total assets worth GBX12.36 Million GBX as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Poolbeg Pharma PLC - Total Assets Trend (2021–2024)
This chart illustrates how Poolbeg Pharma PLC's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Poolbeg Pharma PLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Poolbeg Pharma PLC's total assets of GBX12.36 Million consist of 83.6% current assets and 16.4% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 76.4% |
| Accounts Receivable | GBX519.00K | 5.1% |
| Inventory | GBX0.00 | 0.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX1.68 Million | 16.4% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Poolbeg Pharma PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Poolbeg Pharma PLC's current assets represent 83.6% of total assets in 2024, a decrease from 93.2% in 2021.
- Cash Position: Cash and equivalents constituted 76.4% of total assets in 2024, down from 91.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 6.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 16.4% of total assets.
Poolbeg Pharma PLC Competitors by Total Assets
Key competitors of Poolbeg Pharma PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
ACRO Biomedical Co., Ltd.
TWO:6748
|
Taiwan | NT$607.52 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Poolbeg Pharma PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 24.94 | 19.61 | 175.07 |
| Quick Ratio | 24.94 | 18.49 | 175.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX10.27 Million | GBX10.44 Million | GBX23.10 Million |
Poolbeg Pharma PLC - Advanced Valuation Insights
This section examines the relationship between Poolbeg Pharma PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.72 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -33.6% |
| Total Assets | GBX10.25 Million |
| Market Capitalization | $407.51K USD |
Valuation Analysis
Below Book Valuation: The market values Poolbeg Pharma PLC's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Poolbeg Pharma PLC's assets decreased by 33.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Poolbeg Pharma PLC (2021–2024)
The table below shows the annual total assets of Poolbeg Pharma PLC from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX10.25 Million | -33.58% |
| 2023-12-31 | GBX15.43 Million | -20.02% |
| 2022-12-31 | GBX19.29 Million | -16.20% |
| 2021-12-31 | GBX23.02 Million | -- |
About Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; … Read more